Lasa Supergenerics Ltd

- The company has repaid most of its working capital debt and is currently virtually debt-free. - Remaining debt with Bank of Baroda is under settlement with a verbal nod received for repayment. - No mention of new debt fundraising in the current quarter. - Free cash flow generated will primarily be used for: - Incremental working capital requirements. - Expansion of business (volume growth of existing products). - No discussion or announcement of any current or future equity fundraising. - Management is focused on improving cash flow, return on capital, and utilizing surplus cash for business growth or shareholder rewards (e.g., dividends). - Any additional capacity expansion plans will be internally funded via surplus cash flow. In summary, no explicit plans for new debt or equity fundraising were disclosed; the company prefers leveraging internal accruals to fund growth and working capital needs.

The transcript does not explicitly mention the current or expected order book or pending orders for LASA Supergenerics Limited. However, relevant inferences from the Q&A include: - Exports contribute about 17% directly and around 50% including indirect exports, indicating ongoing orders from international markets. - Competition, especially from China, affects order wins due to their inventory and pricing strategies. - The company strives for consistent topline growth despite market challenges. - The bird flu and COVID-19 vaccine drive may impact demand and government tenders, indicating some uncertainty in order inflow. - Litigation and patent protection efforts are ongoing to protect the company's market share. - Capacity expansions (from 4300 to 5300 MT, with plans for 5800 MT) suggest anticipation of increased order volumes. No specific orderbook value or pending orders were disclosed.